ProCE: The Pharmacy Practice Podcast

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including: Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations Presenters: Kelly Romo, PharmD, BCOP Manager, Oncology Medical Drug Management and Customer Initiatives Blue Cross Blue Shield Michigan Detroit, Michigan Shawna Kraft, PharmD, BCOP Clinical Pharmacist, Specialist Michigan Medicine, Rogel Cancer Center Clinical Associate Professor University of Michigan College of Pharmacy Ann Arbor, Michigan Resources: Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic. 

In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including: An overview of ADC structure and mechanism of action A topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor types An in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategies Editor’s note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy.  Program faculty: Allison Butts, PharmD, BCOP Pharmacist Manager, Oncology Clinical Pharmacist, Breast Oncology UK HealthCare Markey Cancer Center Lexington, Kentucky Danielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Allegheny Health Network Pittsburgh, Pennsylvania Program page: https://bit.ly/4lr7cT6

In this podcast, Brett M. Elicker, MD, and David E. Griffith, MD, ATSF, FACCP, FRSM, discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE, including: The vicious vortex of NCFBE (ie, airway dysfunction, inflammation, infection) Cough as the most significant symptom and burden Imaging bronchiectasis with classic and inflammatory findings Differentiating the causes of NCFBE to inform patient care Presenters Brett M. Elicker, MD Professor of Clinical Radiology Chief, Cardiothoracic Imaging Division Department of Radiology & Biomedical Imaging University of California, San Francisco San Francisco, California David E. Griffith, MD, ATSF, FACCP, FRSM Professor of Medicine Division of Mycobacterial and Respiratory Diseases Department of Medicine National Jewish Health Denver, Colorado Program page:  https://bit.ly/4mZbYsm

Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss how to manage the multidisciplinary care of patients with systemic mastocytosis (SM) from both the allergy/immunology and pharmacy perspective, including: Strategies to better identify patients presenting with features of SM to facilitate timely diagnosis Current guideline-recommended treatment approaches Emerging data on new targeted agents for SM Pharmacist-led strategies to help patients achieve better outcomes (e.g., specialist referral, polypharmacy counseling, and anaphylaxis education) Presenters Jonathan A. Bernstein, MD Professor of Medicine Division of Rheumatology, Allergy and Immunology Department of Internal Medicine University of Cincinnati College of Medicine Partner Advanced Allergy Services, LLC Partner Bernstein Clinical Research Center, LLC Cincinnati, Ohio Ryan Haumschild, PharmD, MS, MBA, CPEL Vice President of Pharmacy, Ambulatory Emory Healthcare Winship Cancer Institute Atlanta, Georgia Full link to program page: https://bit.ly/3HcA8z2

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including: Common comorbidities and complexities in managing patients with HR+/HER2- MBC Treatment landscape for patients with HR+/HER2- MBC Real-world studies in women with HR+/HER2- MBC Mitigation and management of drug interactions and multidisciplinary team coordination treatment selection Patient goals and coordinating with multidisciplinary team to maximize quality of life Link to full program: https://bit.ly/4jCQe38

In this episode, Alexa Basilio, PharmD, BCOP and Jessica Davis, PharmD, BCOP, CPP discuss immune-related adverse events and toxicities among patients using immune checkpoint inhibitors. This overview will include discussion about:  How and when to monitor and treat mild vs severe immune-related toxicities The art of balancing and tapering low-dose and high-dose corticosteroids Differentiating between immune-related and chemotherapy- or targeted therapy–associated adverse events for optimal management approaches Involvement of multidisciplinary teams early during treatment to prevent immune-related adverse events Importance of educating patients, caregivers, and providers on immune-related toxicities Presenters:  Alexa Basilio, PharmD, BCOP University of Florida College of Pharmacy  Oncology Pharmacy Specialist  McKesson, The US Oncology Network Tampa, Florida  Jessica Davis, PharmD, BCOP, CPP  Levine Cancer Institute Clinical Pharmacist Coordinator, Adult Hematology/Oncology Atrium Health Levine Center Charlotte, North Carolina  Link to full program:  https://bit.ly/3We4HJy

In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to: Engage key stakeholders in the provision of HBV care​ Provide HBV management resources to support PCPs who are doing screening​ Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBV Presenters: Su Wang, MD, MPH, FACP Medical Director Center for Asian Health and Viral Hepatitis Programs Cooperman Barnabas Medical Center RWJBarnabas-Rutgers Medical Group Associate Member Health Care Policy and Aging Research The Rutgers Institute for Health Senior Advisor Global Health, Hepatitis B Foundation Florham Park, New Jersey Richard R. Andrews, MD, MPH President, Houston Viral Hepatitis Task Force Former Co-Chair, National Task Force on Hepatitis B Board-Certified Family Medicine Addiction Medicine Physician Houston, Texas Ruth Brogden, MPH Patient Advocate Amy S. Tang, MD Former Co-Chair, National Task Force on Hepatitis B Director of Immigrant Health North East Medical Services San Francisco, California Link to full program:  https://bit.ly/3TuqFHI

In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include: Patient subgroups to consider for treatment outside guideline criteria Adverse event and cost-effectiveness considerations Integration of patient perspectives in wider treatment Presenters: Mark S. Sulkowski, MD, FIDSA, FAASLD Professor of Medicine Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center Johns Hopkins University School of Medicine Baltimore, Maryland Tatyana Kushner, MD, MSCE Associate Professor Division of Liver Diseases Icahn School of Medicine at Mount Sinai New York, New York Paul Y. Kwo, MD Professor of Medicine Director of Hepatology Stanford University School of Medicine Palo Alto, California Jacki Chen, PhD Patient Advocate  Link to full program:  https://bit.ly/3TuqFHI Link to the slides: https://bit.ly/4a60GM4 Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include: Updated CDC recommendations for one-time universal screening for HBV Addressing patient-, provider-, and system-level barriers to universal HBV screening Best practices for implementation of HDV screening Presenters: Douglas Dieterich, MD Director, Institute for Liver Medicine Professor of Medicine Division of Liver Diseases Mount Sinai School of Medicine New York, New York Camilla S. Graham, MD, MPH Co-Director, Viral Hepatitis Clinic Division of Infectious Diseases Beth Israel Deaconess Medical Center Harvard Medical School Boston, Massachusetts Robert Wong, MD, MS  Clinical Associate Professor Division of Gastroenterology and Hepatology Stanford University School of Medicine Palo Alto, California Link to full program: https://bit.ly/3TuqFHI Link to the slides:  https://bit.ly/4atS42z

In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including: Burden of CRE infections in the United States Mechanisms of resistance Changing epidemiology Use of rapid diagnostic tests IDSA guidance recommendations, including supporting data Approach to designing treatment regimens, including weighing patient- and infection-related factors Faculty: Julie Ann Justo, PharmD, MS, FIDSA, BCPS Clinical Pharmacist Lead – Infectious Diseases Inpatient Pharmacy Dartmouth Hitchcock Medical Center Lebanon, New Hampshire Link to full program:  https://bit.ly/41a8Mj0 Link to downloadable infographic:  https://bit.ly/3t7NpT2

In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman provide practical strategies for implementing RSV vaccination into practice, including:  Educating older adults on RSV vaccines  Providing effective, evidence-based recommendations Shared decision-making  Identifying and addressing vaccine hesitancy  Proactive strategies in vaccinating for RSV  Predicting and overcoming barriers to RSV vaccination  Presenters: Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey Internal Medicine Pharmacist Robert Wood Johnson University Hospital New Brunswick, New Jersey Christina M. Madison, PharmD, FCCP, AAHIVP Clinical Pharmacist Founder and CEO, The Public Health Pharmacist, PLLC Adjunct Associate Professor of Pharmacy Practice Roseman University of Health Sciences College of Pharmacy Henderson, Nevada Other program activities:  Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role  https://bit.ly/49GUv1g Link to CME: Claim Credit –  https://bit.ly/3uoY7VH [After selecting the “Continue to Post Test” button:] To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.

In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman discuss the latest practical strategies for preventing RSV infection in older adults, including:  Role of basic public health precautions Available and emerging vaccines Mechanisms of action, therapeutic targets, and pharmacology Efficacy and safety data FDA approval status and ACIP recommendations Presenters:   Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey Internal Medicine Pharmacist Robert Wood Johnson University Hospital New Brunswick, New Jersey Christina M. Madison, PharmD, FCCP, AAHIVP   Clinical Pharmacist Founder and CEO, The Public Health Pharmacist, PLLC Adjunct Associate Professor of Pharmacy Practice Roseman University of Health Sciences College of Pharmacy Henderson, Nevada Other program activities:   • Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role         

In this accredited podcast episode, Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP, discusses the most important things for pharmacists across all settings to know about RSV infections in patients 60 years of age or older, including:  Incidence and prevalence of RSV in older adults, including hospitalization, mortality, epidemiology Seasonality Clinical manifestations Risk factors for severe outcomes Vulnerable groups and comorbidities Presenter: Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey Internal Medicine Pharmacist Robert Wood Johnson University Hospital New Brunswick, New Jersey Other program activities:  Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role  https://bit.ly/49GUv1g Link to CME: Claim Credit – https://bit.ly/47GtNnK [After selecting the “Continue to Post Test” button:] To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.

In this episode, Sarah Hayward, PharmD, BCOP, and Amy Ly Indorf, PharmD, BCOP, discuss their experiences providing care for patients with advanced ovarian cancer, with topics including: PARP inhibitors as frontline maintenance therapy Patient education and counseling on PARP inhibitors Helping patients access newer therapies Experiences with mirvetuximab soravtansine Patient education and counseling on mirvetuximab soravtansine Treatment modalities on the horizon  Presenters: Sarah Hayward, PharmD, BCOP Clinical Pharmacy Specialist, Gynecologic Oncology Stephenson Cancer Center at OU Health Oklahoma City, Oklahoma Amy Ly Indorf, PharmD, BCOP Clinical Assistant Professor University of Washington  School of Pharmacy Clinical Oncology Pharmacist UW Medicine Fred Hutchinson Cancer Center Seattle, Washington Supported by educational grants from GSK and Novocure, Inc. Link to full program: https://bit.ly/44fUiOU  

In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including: Current COVID-19 landscape Rapid antigen tests and PCR tests Risk stratification of patients who have a positive SARS-CoV-2 test Antiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir) Long COVID Presenters: Renslow Sherer, MD Director, International HIV Training Center Professor of Medicine Section of Infectious Diseases and Global Health Department of Medicine University of Chicago Chicago, Illinois Trinh P. Vu, PharmD, BCIDP Clinical Pharmacy Specialist in Infectious Diseases Department of Pharmaceutical Services Emory University Hospital Midtown Atlanta, Georgia To download the slides: bit.ly/3oHKC09 To view the full online program: bit.ly/4201xcO

In this episode, pharmacists Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM, and Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP, discuss the use of GLP-1 receptor agonists in patients with type 2 diabetes and provide answers to commonly asked questions. Listen to their conversation about the differences between short-acting vs long-acting agents; the benefits of use in combination with other medications, such as SGLT2 inhibitors, DPP-4 inhibitors, and metformin; their benefits in heart failure; and their role in the updated consensus statement from the American Diabetes Association/European Association for the Study of Diabetes.  Presenters: Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM Clinical Professor Department of Pharmacy Practice Auburn University Harrison College of Pharmacy Clinical Pharmacist Baptist Health Foundation Center for Medical and Surgical Care Princeton Baptist Medical Center/Brookwood Baptist Health Birmingham, Alabama Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP Professor Department of Pharmacy Practice Midwestern University College of Pharmacy Downers Grove, Illinois Clinical Pharmacist Advocate Medical Group Chicago, Illinois Content based on an online CE program supported by an educational grant from Novo Nordisk, Inc. Link to full program:  https://bit.ly/3Un1xQi

In this episode, Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, and Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, discuss the use of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes, including: Overview of chronic kidney disease Guideline recommendations Evidence for finerenone Role of the pharmacist Presenter: Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP Endocrine Clinical Pharmacy Specialist CGM and Remote Monitoring Program Coordinator Endocrinology and Metabolism Institute Cleveland Clinic Cleveland, Ohio Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP Vice Chair and Allen I. White Distinguished Professor Department of Pharmacotherapy College of Pharmacy and Pharmaceutical Sciences   Washington State University Spokane, Washington Review the downloadable slideset and the full program at: https://bit.ly/3wxNAod

This podcast is the third in a series of three featuring insights from expert cardiology pharmacists on nonvalvular atrial fibrillation (NVAF). In this episode, pharmacist Kathleen A. Lusk, PharmD, BCPS, BCCP, provides an overview of health disparities, patient engagement, and collaborative team-based care to optimize outcomes for patients with NVAF. Dr Lusk reviews best practices in using the principles of motivational interviewing to employ shared decision-making and models these strategies with 2 simulated clinical patient visits. Common barriers, such as medication access and adherence, also are discussed, along with practical solutions for overcoming these care obstacles.  Presenter: Kathleen A. Lusk, PharmD, BCPS, BCCP Associate Professor and Vice Chair Department of Pharmacy Practice University of the Incarnate Word Feik School of Pharmacy  Adjunct Assistant Professor Clinical Pharmacy Specialist Division of Cardiology Department of Medicine UT Health San Antonio San Antonio, Texas Content is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance. This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go to: https://bit.ly/3OMazV8

This podcast is the first in a series of three featuring cardiology pharmacists Kathleen A. Lusk, PharmD, BCPS, BCCP, and Stephanie Dwyer Kaluzna, PharmD, BCCP. In this episode, Drs Lusk and Dwyer Kaluzna provide an overview of nonvalvular atrial fibrillation (NVAF), including prevalence, burden, and consequences of undiagnosed NVAF and the role of pharmacists in screening for the condition in various pharmacy settings. Presenters: Kathleen A. Lusk, PharmD, BCPS, BCCP   Associate Professor and Vice Chair   Department of Pharmacy Practice University of the Incarnate Word Feik School of Pharmacy   Adjunct Assistant Professor Clinical Pharmacy Specialist Division of Cardiology Department of Medicine UT Health San Antonio San Antonio, Texas Stephanie Dwyer Kaluzna, PharmD, BCCP   Clinical Assistant Professor Department of Pharmacy Practice University of Illinois Chicago College of Pharmacy Cardiovascular Clinical Pharmacist University of Illinois Hospital and Health Science System Chicago, Illinois Content is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance. This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go to https://bit.ly/3OMazV8

This podcast is the second in a series of three featuring insights from expert cardiology pharmacists on nonvalvular atrial fibrillation (NVAF). In this episode, cardiology pharmacist Stephanie Dwyer Kaluzna, PharmD, BCCP, reviews key literature and guideline recommendations for stroke prevention in patients with NVAF. Dr Dwyer Kaluzna discusses the most recent evidence for prescribing, dosing, and monitoring direct oral anticoagulants (DOACs); using the risk-screening tools HAS-BLED and CHA2DS2-VASc to design patient-specific pharmacotherapy plans; and the use of DOACs in special patient populations, including older patients, patients with end-stage renal disease, and patients with low or high body weights. Presenter: Stephanie Dwyer Kaluzna, PharmD, BCCP   Clinical Assistant Professor Department of Pharmacy Practice University of Illinois Chicago College of Pharmacy Cardiovascular Clinical Pharmacist University of Illinois Hospital and Health Science System Chicago, Illinois Content is based on an online CE program supported by an educational grant from the Bristol Myers Squibb Pfizer Alliance. This podcast series was first delivered as live webinars, which are now available as on-demand, CE-certified microlearning modules with downloadable slidesets. The program also features a ClinicalThought commentary and a downloadable infographic reference guide. To access the full program, go to https://bit.ly/3OMazV8